OBJECTIVE: Previous reports described the prognostic value of the serum CA125 level after primary treatment (CA125 nadir) in a selection of ovarian cancer patients. Our primary objective was to determine whether the CA125 nadir level is of prognostic value on the progression-free survival (PFS) and on overall survival (OS) in epithelial ovarian cancer (EOC) patients in all stages of disease who reached complete remission (CR). METHODS: Patients were selected from a population-based study on EOC patients diagnosed between 1996 and 2006 in 11 Dutch hospitals. All 331 patients who reached CR (i.e. no physical or radiological signs of residual disease and CA125 values ≤35 kU/L) after primary treatment were included. The Kaplan-Meier survival curves of PFS and OS in CA125 nadir ≤5 kU/L and >5 kU/L were compared using the log-rank test. Multivariate Cox regression analyses were performed to study the factors that independently influence survival. RESULTS: A CA125 nadir ≤5 kU/L (n=69) was significantly associated with both a longer PFS and longer OS (log-rank test P<0.01 and P=0.03, respectively). The CA125 nadir was an independent prognostic variable (HR=1.51, 95% CI: 1.04-2.31) for PFS next to histological type, FIGO stage and residual tumor after surgery. CONCLUSIONS: EOC patients who were in CR after standard primary treatment and attained CA125 nadir values of ≤5 kU/L had a significantly longer PFS and OS. Moreover, the CA125 nadir of ≤5 kU/L is an independent predictor of tumor recurrence.
OBJECTIVE: Previous reports described the prognostic value of the serum CA125 level after primary treatment (CA125nadir) in a selection of ovarian cancerpatients. Our primary objective was to determine whether the CA125nadir level is of prognostic value on the progression-free survival (PFS) and on overall survival (OS) in epithelial ovarian cancer (EOC) patients in all stages of disease who reached complete remission (CR). METHODS:Patients were selected from a population-based study on EOC patients diagnosed between 1996 and 2006 in 11 Dutch hospitals. All 331 patients who reached CR (i.e. no physical or radiological signs of residual disease and CA125 values ≤35 kU/L) after primary treatment were included. The Kaplan-Meier survival curves of PFS and OS in CA125nadir ≤5 kU/L and >5 kU/L were compared using the log-rank test. Multivariate Cox regression analyses were performed to study the factors that independently influence survival. RESULTS: A CA125nadir ≤5 kU/L (n=69) was significantly associated with both a longer PFS and longer OS (log-rank test P<0.01 and P=0.03, respectively). The CA125nadir was an independent prognostic variable (HR=1.51, 95% CI: 1.04-2.31) for PFS next to histological type, FIGO stage and residual tumor after surgery. CONCLUSIONS: EOC patients who were in CR after standard primary treatment and attained CA125nadir values of ≤5 kU/L had a significantly longer PFS and OS. Moreover, the CA125nadir of ≤5 kU/L is an independent predictor of tumor recurrence.
Authors: Iván Díaz-Padilla; Albiruni Ryan Abdul Razak; Lucas Minig; Marcus Q Bernardini; Josep María Del Campo Journal: Clin Transl Oncol Date: 2012-01 Impact factor: 3.405
Authors: Robert M Trout; Einstein Gnanatheepam; Ahmed Gado; Christopher Reik; Jessica C Ramella-Roman; Martin Hunter; Thomas Schnelldorfer; Irene Georgakoudi Journal: Biomed Opt Express Date: 2022-01-05 Impact factor: 3.562
Authors: Xiaoxiang Chen; Jing Zhang; Wenjun Cheng; Doo Young Chang; Jianfei Huang; Xuan Wang; Lizhou Jia; Daniel G Rosen; Wei Zhang; Da Yang; David M Gershenson; Anil K Sood; Robert C Bast; Jinsong Liu Journal: Int J Gynecol Cancer Date: 2013-06 Impact factor: 3.437